Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00046228 · ClinicalTrials.gov registry record · Phase 3
A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)
A Phase 3 study, sponsored by Centocor.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,461
- Enrollment target
NCT00046228: Completed Phase 3 study, sponsored by Centocor.
NCT00046228 is a Phase 3 study that has completed, run by Centocor. The registered enrollment target is 2,461 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (219% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00046228, a Phase 3 study, has completed, sponsored by Centocor.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,461 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether abciximab given in combination with reteplase, before patients have a coronary intervention (a standard treatment where a catheter is inserted into the heart artery to get blood flowing past the clot), is safe and effective in the treatment of heart attacks compared to only abciximab given during coronary intervention.
Primary Outcome
Occurs within 90 days and is composite of all-cause mortality or complications of myocardial infarction (MI) (rehospitalization or emergency department visit for congestive heart failure (CHF), cardiogenic shock, or resuscitated ventricular fibrillation occurring \> 48 hours after randomization).
Interventions
- DRUG abciximab placebo; reteplase placebo, abciximab, abciximab
- DRUG Abciximab; reteplase; abciximab placebo; abciximab
- DRUG abciximab; reteplase placebo; abciximab placebo; abciximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,461 participants |
| Start Date | 2002-08 |
| Est. Completion | 2008-01 |
| Phase | Phase 3 |
What the finished NCT00046228 record still lists
NCT00046228 is an interventional study that assigns participants to a tested intervention. Its 2,461 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (219% higher).
The record links to 0 conditions, and to 3 interventions - of which abciximab placebo; reteplase placebo, abciximab, abciximab is the first listed.
NCT00046228 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00046228 about?
NCT00046228 is a clinical study titled "A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)". The purpose of this study is to determine whether abciximab given in combination with reteplase, before patients have a coronary intervention (a standard treatment where a catheter is inserted into the heart artery to get blood flowing past the clot), is safe and effective in the treatment of heart ...
What is the current status of trial NCT00046228?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,461 participants. The study started on 2002-08. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00046228?
The interventions under investigation include: abciximab placebo; reteplase placebo, abciximab, abciximab (DRUG), Abciximab; reteplase; abciximab placebo; abciximab (DRUG), abciximab; reteplase placebo; abciximab placebo; abciximab (DRUG).
Who is sponsoring clinical trial NCT00046228?
This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00046228's enrollment target sits among peer trials
2,461 88th of 2000 higher than 1,913 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06898593 · 2,448 participants · NA
Enhancing Engagement by Integrating Goals and Concerns That Matter to Patients
- NCT06128304 · 2,436 participants · NA
ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services
- NCT06676904 · 2,433 participants · NA
Neonatal Platelet Transfusion Threshold Trial
- NCT05345951 · 2,425 participants · NA
Project e-PBI+ - Parent Intervention to Reduce College Student Drinking and Cannabis Use
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia